We reported that the overexpression of both ETS1 and TGM2 could induce aggressive phenotypes and drug resistance in CRC, at least in part, owing to their promoting effects on Wnt/β-catenin signaling. The gene discussed is ETS1; the disease is colorectal carcinoma.